{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:48:05Z","timestamp":1762876085077,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3394-4","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T14:02:27Z","timestamp":1558965747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5946-2128","authenticated-orcid":false,"given":"Mohammed S.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Perlas","family":"Asonto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M.","family":"El Tahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal H.","family":"Al Sulaibikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukayna Z.","family":"Al Faraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah A.","family":"Al Mulhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad F.","family":"Al Abbad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar A.","family":"Al Nahhash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moath N.","family":"Aldarweesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisreen","family":"Almaghraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Al Jumaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamir O.","family":"Al Junaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal M.","family":"Al Hawaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"AlKenany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omaima F.","family":"ElSayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitham M.","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bader K.","family":"Alossaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaikah K.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal M.","family":"AlMutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duaa A.","family":"AlSulaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad D.","family":"Al Shahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donia","family":"Alfaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Alhazzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"3394_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4172\/2155-6148.1000394","volume":"5","author":"CM Neri","year":"2014","unstructured":"Neri CM, Pestieau SR, Young H, et al. Low-dose ketamine for children and adolescents with acute sickle cell disease related pain: a single center experience. J Anesth Clin Res. 2014;5:394. https:\/\/doi.org\/10.4172\/2155-6148.1000394 .","journal-title":"J Anesth Clin Res"},{"key":"3394_CR2","first-page":"40","volume":"112","author":"H Davis","year":"1997","unstructured":"Davis H, Moore RM, Gergen PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 1997;112:40\u20133.","journal-title":"Public Health Rep"},{"key":"3394_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.10305","volume":"72","author":"P Houston-Yu","year":"2003","unstructured":"Houston-Yu P, Rana SR, Beyer B, et al. Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol. 2003;72:201\u20133.","journal-title":"Am J Hematol"},{"key":"3394_CR4","first-page":"2249","volume":"122","author":"A Chu","year":"2013","unstructured":"Chu A, Golembiewski J, Molokie RE. Low-dose ketamine infusion in adult patients with sickle cell disease\u2014impact on management of acute painful episodes. Am Soc Hematol. 2013;122:2249.","journal-title":"Am Soc Hematol"},{"key":"3394_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ajem.2009.01.016","volume":"28","author":"B Uzun","year":"2010","unstructured":"Uzun B, Kekec Z, Gurkan E. Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis. Am J Emerg Med. 2010;28:445\u20139.","journal-title":"Am J Emerg Med"},{"key":"3394_CR6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0196-0644(88)80554-7","volume":"17","author":"ER Gonzalez","year":"1988","unstructured":"Gonzalez ER, Ornato JP, Ware D, et al. Comparison of intramuscular analgesic activity of butorphanol and morphine in patients with sickle cell disease. Ann Emerg Med. 1988;17:788\u201391.","journal-title":"Ann Emerg Med"},{"key":"3394_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(97)08462-6","volume":"350","author":"SJ Jacobson","year":"1997","unstructured":"Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997;350:1358\u201361.","journal-title":"Lancet"},{"key":"3394_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0196-0644(05)82929-4","volume":"21","author":"SW Wright","year":"1992","unstructured":"Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med. 1992;21:925\u20138.","journal-title":"Ann Emerg Med"},{"key":"3394_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.7326\/0003-4819-116-5-364","volume":"116","author":"D Brookoff","year":"1992","unstructured":"Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med. 1992;116:364\u20138.","journal-title":"Ann Intern Med"},{"key":"3394_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0027-9684(15)30729-X","volume":"102","author":"LR Solomon","year":"2010","unstructured":"Solomon LR. Pain management in adults with sickle cell disease in a medical center emergency department. J Natl Med Assoc. 2010;102:1025\u201332.","journal-title":"J Natl Med Assoc"},{"key":"3394_CR11","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jpainsymman.2011.06.003","volume":"42","author":"CG Meals","year":"2011","unstructured":"Meals CG, Mullican BD, Shaffer CM, et al. Ketamine infusion for sickle cell crisis pain in an adult. J Pain Symptom Manag. 2011;42:e7\u20139.","journal-title":"J Pain Symptom Manag"},{"key":"3394_CR12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.36076\/ppj.2007\/10\/493","volume":"10","author":"T Okon","year":"2007","unstructured":"Okon T. Ketamine: an introduction for the pain and palliative medicine physician. Pain Physician. 2007;10:493\u2013500.","journal-title":"Pain Physician"},{"key":"3394_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/AJP.0b013e3181b511ab","volume":"26","author":"WT Zempsky","year":"2010","unstructured":"Zempsky WT, Loiselle KA, Corsi JM, et al. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain. 2010;26:163\u20137.","journal-title":"Clin J Pain"},{"key":"3394_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jpainsymman.2013.03.012","volume":"47","author":"QA Tawfic","year":"2014","unstructured":"Tawfic QA, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. J Pain Symptom Manag. 2014;47:334\u201340.","journal-title":"J Pain Symptom Manag"},{"key":"3394_CR15","first-page":"1095","volume":"35","author":"S Motov","year":"2017","unstructured":"Motov S, Mai M, Pushkar I, et al. A prospective randomized, double-dummy trial comparing IV push low dose ketamine to short infusion of low dose ketamine for treatment of pain in the ED. J Pain Symptom Manag. 2017;35:1095\u2013100.","journal-title":"J Pain Symptom Manag"},{"key":"3394_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/pme.12705","volume":"16","author":"TL Ahern","year":"2015","unstructured":"Ahern TL, Herring AA, Miller S, et al. Low-dose ketamine infusion for emergency department patients with severe pain. Pain Med. 2015;16:1402\u20139.","journal-title":"Pain Med"},{"key":"3394_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200\u20137.","journal-title":"Ann Intern Med"},{"key":"3394_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1515\/sjpain-2017-0140","volume":"18","author":"FA Lubega","year":"2018","unstructured":"Lubega FA, DeSilva MS, Munube D, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018;18:19\u201327.","journal-title":"Scand J Pain"},{"key":"3394_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1213\/XAA.0000000000000624","volume":"10","author":"AC Gimovsky","year":"2018","unstructured":"Gimovsky AC, Fritton K, Viscusi E, et al. Evaluating the use of ketamine for pain control with sickle cell crisis in pregnancy: a report of 2 cases. A A Pract. 2018;10:20\u20132.","journal-title":"A A Pract"},{"key":"3394_CR20","doi-asserted-by":"publisher","unstructured":"Palm N, Floroff C, Hassig TB, et al. Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. J Pain Palliat Care Pharmacother. 2018:1\u20137. https:\/\/doi.org\/10.1080\/15360288.2018.1468383 .","DOI":"10.1080\/15360288.2018.1468383"},{"key":"3394_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/pr.2017.197","volume":"83","author":"R Nobrega","year":"2018","unstructured":"Nobrega R, Sheehy KA, Lippold C, et al. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. Pediatr Res. 2018;83:445\u201354.","journal-title":"Pediatr Res"},{"key":"3394_CR22","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/acem.12510","volume":"21","author":"FL Beaudoin","year":"2014","unstructured":"Beaudoin FL, Lin C, Guan W, et al. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial. Acad Emerg Med. 2014;21:1193\u2013202.","journal-title":"Acad Emerg Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3394-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3394-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3394-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T18:13:27Z","timestamp":1663524807000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3394-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3394"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3394-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"12 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This protocol is designed according to the new paragraph\u00a06 of the Declaration of Helsinki (Edinburgh Update, 2000), which states that even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility, and quality [].Prior to the start of the study, the protocol and the informed consent form and other applicable documentation was submitted to and approved by our local Institutional Review Board (IRB 2016\u201301-042). Documentation of Ethics Committee\/IRB approvals are required before projects are activated to register and enroll patients. Enrollment began in February 2018.We anticipate completion of enrollment by the end of January 2019.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No patients were involved in the trial design or recruitment, or in any part of the study methods.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"286"}}